Formation of an N-formylkynurenine-derived fluorophore and its use for measuring indoleamine 2,3-dioxygenase 1 activity

[1]  P. O'dwyer,et al.  Pharmacodynamic assessment of INCB024360, an inhibitor of indoleamine 2,3-dioxygenase 1 (IDO1), in advanced cancer patients. , 2012 .

[2]  S. Wang,et al.  Upregulated Expression of Indoleamine 2, 3-Dioxygenase in Primary Breast Cancer Correlates with Increase of Infiltrated Regulatory T Cells In Situ and Lymph Node Metastasis , 2011, Clinical & developmental immunology.

[3]  G. Prendergast,et al.  Cancer: Why tumours eat tryptophan , 2011, Nature.

[4]  Emma Lloyd Raven,et al.  The Mechanism of Formation of N-Formylkynurenine by Heme Dioxygenases , 2011, Journal of the American Chemical Society.

[5]  K. Chida,et al.  Increased serum kynurenine/tryptophan ratio correlates with disease progression in lung cancer. , 2010, Lung cancer.

[6]  S. Rutella,et al.  Inhibitors of indoleamine 2,3-dioxygenase: a review of novel patented lead compounds , 2010, Expert opinion on therapeutic patents.

[7]  H. Kajiyama,et al.  Role of the immunosuppressive enzyme indoleamine 2,3-dioxygenase in the progression of ovarian carcinoma. , 2009, Gynecologic oncology.

[8]  C. L. Costantino,et al.  Expression of indoleamine 2,3-dioxygenase in metastatic malignant melanoma recruits regulatory T cells to avoid immune detection and affects survival , 2009, Cell cycle.

[9]  Qian Wang,et al.  Discovery of potent competitive inhibitors of indoleamine 2,3-dioxygenase with in vivo pharmacodynamic activity and efficacy in a mouse melanoma model. , 2009, Journal of medicinal chemistry.

[10]  H. Ball,et al.  Indoleamine 2,3-dioxygenase-2; a new enzyme in the kynurenine pathway. , 2009, The international journal of biochemistry & cell biology.

[11]  L. Bubendorf,et al.  High expression of indoleamine 2,3-dioxygenase gene in prostate cancer. , 2008, European journal of cancer.

[12]  Judith M. LaLonde,et al.  Structure based development of phenylimidazole-derived inhibitors of indoleamine 2,3-dioxygenase. , 2008, Journal of medicinal chemistry.

[13]  G. Prendergast.  Immune escape as a fundamental trait of cancer: focus on IDO , 2008, Oncogene.

[14]  Judith M. LaLonde,et al.  Indoleamine 2,3-dioxygenase is the anticancer target for a novel series of potent naphthoquinone-based inhibitors. , 2008, Journal of medicinal chemistry.

[15]  I. Melero,et al.  Immunosuppression routed via the kynurenine pathway: a biochemical and pathophysiologic approach. , 2008, Advances in clinical chemistry.

[16]  G. Prendergast,et al.  Inhibition of indoleamine 2,3-dioxygenase in dendritic cells by stereoisomers of 1-methyl-tryptophan correlates with antitumor responses. , 2007, Cancer research.

[17]  David J. Freeman,et al.  Reinstalling Antitumor Immunity by Inhibiting Tumor-Derived Immunosuppressive Molecule IDO through RNA Interference1 , 2006, The Journal of Immunology.

[18]  Stefan Schneeberger,et al.  Prognostic value of indoleamine 2,3-dioxygenase expression in colorectal cancer: effect on tumor-infiltrating T cells. , 2006, Clinical cancer research : an official journal of the American Association for Cancer Research.

[19]  R. Truscott,et al.  A fluorescence-based assay for indoleamine 2,3-dioxygenase. , 2006, Analytical biochemistry.

[20]  G. Prendergast,et al.  Marrying immunotherapy with chemotherapy: why say IDO? , 2005, Cancer research.

[21]  Álvaro González,et al.  Tryptophan metabolites interfere with the Ehrlich reaction used for the measurement of kynurenine. , 2005, Analytical biochemistry.

[22]  M. Lhermitte,et al.  Simultaneous determination of tryptophan and kynurenine in serum by HPLC with UV and fluorescence detection. , 2004, Biomedical chromatography : BMC.

[23]  M. Parker,et al.  Optimised expression and purification of recombinant human indoleamine 2,3-dioxygenase. , 2004, Protein expression and purification.

[24]  C. Uyttenhove,et al.  Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase , 2003, Nature Medicine.

[25]  T. Stone,et al.  Endogenous kynurenines as targets for drug discovery and development , 2002, Nature Reviews Drug Discovery.

[26]  D. Fuchs,et al.  Serum tryptophan decrease correlates with immune activation and impaired quality of life in colorectal cancer , 2002, British Journal of Cancer.

[27]  D. Fuchs,et al.  More rapid method for simultaneous measurement of tryptophan and kynurenine by HPLC. , 2002, Clinical chemistry.

[28]  D. Fuchs,et al.  Increased neopterin production and tryptophan degradation in advanced Parkinson's disease , 2002, Journal of Neural Transmission.

[29]  D. Fuchs,et al.  Tryptophan degradation and immune activation in Alzheimer's disease , 2000, Journal of Neural Transmission.

[30]  U. Haupts,et al.  Homogeneous fluorescence readouts for miniaturized high-throughput screening: theory and practice. , 1999, Drug discovery today.

[31]  Thomas D. Y. Chung,et al.  A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays , 1999, Journal of biomolecular screening.

[32]  J. Dawson,et al.  Heme-Containing Oxygenases. , 1996, Chemical reviews.

[33]  M. Sono.  Spectroscopic and equilibrium studies of ligand and organic substrate binding to indolamine 2,3-dioxygenase. , 1990, Biochemistry.

[34]  O. Takikawa,et al.  Mechanism of interferon-gamma action. Characterization of indoleamine 2,3-dioxygenase in cultured human cells induced by interferon-gamma and evaluation of the enzyme-mediated tryptophan degradation in its anticellular activity. , 1988, The Journal of biological chemistry.

[35]  C. I. Pogson,et al.  Indoleamine 2,3-dioxygenase. A new, rapid, sensitive radiometric assay and its application to the study of the enzyme in rat tissues. , 1980, The Biochemical journal.

[36]  C. E. Dalgliesh.  29. The synthesis of N′-formyl-DL-kynurenine, Nα-acetyl-DL-kynurenine and related compounds, and observations on the synthesis of kynurenine , 1952 .